The Life Expectancy Gap is Shrinking
When is it a good thing to be told the life expectancy of a person with Type 1 diabetes is 11 to 13 years shorter than the lifespan of the average population? When that difference in lifespan used to span more than two decades.
A pair of new studies seems to indicate that newer forms of intensive insulin therapy is keeping people with Type 1 diabetes alive longer. Recent research examining public health records in Scotland found that the average lifespan of a person with Type 1 diabetes was 11 years shorter for men and 13 years shorter for women than the average lifespan of those without Type 1 diabetes, according to Medical News Today. At the same time, another study published in the Journal of the American Medical Association found that intensive insulin therapy modestly reduced all-cause mortality for people with Type 1 diabetes. Previously, the lifespan gap between people with Type 1 and people without reached up to 27 years. Diabetes researchers, however, stressed that no difference in lifespan is acceptable.
Another Stem Cell Research Dustup
What is it about stem cell studies that make them so prone to their validity being questioned?
The therapy, which holds the promise of generating insulin-producing beta cells for people with Type 1 diabetes, has come under scrutiny again, according to a Fierce BioTech Research report. Two stem cell researchers are suing Harvard University and Brigham & Women’s hospital for allegedly mishandling investigations into problems with their stem cell research. The two researchers say the irregularities were caused by a third researcher, but that the supposedly-botched investigations destroyed their reputations. The stem cell research in question was for heart tissue regeneration, not diabetes research, but it is one of a long list of stem cell studies under fire, which could chill the climate for such therapy.
Jury’s Still Out for the Type 1 Gluten-Free Diet
U.S. Children Have a Higher Rate of DKA